HIV-specific T-cell induction
AssigneeBoard of Regents, The University of Texas System
InventorsK. Jagannadha Sastry, Ralph B. Arlinghaus, Pramod N. Nehete
Life of this patent
Estimating the term…
Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsK. Jagannadha Sastry, Ralph B. Arlinghaus, Pramod N. Nehete
Estimating the term…
This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.
A method of treating an HIV infection in a human subject comprising administering to said subject a synthetic peptide composition comprising at least the sequence of SEQ ID NO:20, 21, 22, 23, 24, 25 or 40.
Dependencies are inferred from the claim text.